Advances in Cutaneous Squamous Cell Carcinoma Management
cSCC is increasing in prevalence due to increased lifespans and improvements in survival for conditions that increase the risk of cSCC. The absolute mortality of cSCC exceeds melanoma in the United States and approaches that of melanoma worldwide. This review presents significant changes in the mana...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-07-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/15/3653 |
| _version_ | 1797414490469302272 |
|---|---|
| author | Carrick Burns Shelby Kubicki Quoc-Bao Nguyen Nader Aboul-Fettouh Kelly M. Wilmas Olivia M. Chen Hung Quoc Doan Sirunya Silapunt Michael R. Migden |
| author_facet | Carrick Burns Shelby Kubicki Quoc-Bao Nguyen Nader Aboul-Fettouh Kelly M. Wilmas Olivia M. Chen Hung Quoc Doan Sirunya Silapunt Michael R. Migden |
| author_sort | Carrick Burns |
| collection | DOAJ |
| description | cSCC is increasing in prevalence due to increased lifespans and improvements in survival for conditions that increase the risk of cSCC. The absolute mortality of cSCC exceeds melanoma in the United States and approaches that of melanoma worldwide. This review presents significant changes in the management of cSCC, focusing on improvements in risk stratification, new treatment options, optimization of existing treatments, and prevention strategies. One major breakthrough in cSCC treatment is the advent of immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1), which have ushered in a renaissance in the treatment of patients with locally advanced and metastatic disease. These agents have offered patients with advanced disease decreased therapeutic toxicity compared to traditional chemotherapy agents, a more durable response after discontinuation, and improved survival. cSCC is an active field of research, and this review will highlight some of the novel and more developed clinical trials that are likely to impact cSCC management in the near future. |
| first_indexed | 2024-03-09T05:34:01Z |
| format | Article |
| id | doaj.art-f72e81260eeb496591a7433bee9b3b2b |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T05:34:01Z |
| publishDate | 2022-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-f72e81260eeb496591a7433bee9b3b2b2023-12-03T12:30:44ZengMDPI AGCancers2072-66942022-07-011415365310.3390/cancers14153653Advances in Cutaneous Squamous Cell Carcinoma ManagementCarrick Burns0Shelby Kubicki1Quoc-Bao Nguyen2Nader Aboul-Fettouh3Kelly M. Wilmas4Olivia M. Chen5Hung Quoc Doan6Sirunya Silapunt7Michael R. Migden8Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USADepartment of Dermatology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USADepartment of Dermatology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USADepartment of Dermatology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USADepartment of Dermatology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USADepartment of Dermatology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USADepartment of Dermatology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USADepartment of Dermatology, University of Texas McGovern Medical School at Houston, 6655 Travis St. Suite 700, Houston, TX 77030, USADepartments of Dermatology and Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USAcSCC is increasing in prevalence due to increased lifespans and improvements in survival for conditions that increase the risk of cSCC. The absolute mortality of cSCC exceeds melanoma in the United States and approaches that of melanoma worldwide. This review presents significant changes in the management of cSCC, focusing on improvements in risk stratification, new treatment options, optimization of existing treatments, and prevention strategies. One major breakthrough in cSCC treatment is the advent of immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1), which have ushered in a renaissance in the treatment of patients with locally advanced and metastatic disease. These agents have offered patients with advanced disease decreased therapeutic toxicity compared to traditional chemotherapy agents, a more durable response after discontinuation, and improved survival. cSCC is an active field of research, and this review will highlight some of the novel and more developed clinical trials that are likely to impact cSCC management in the near future.https://www.mdpi.com/2072-6694/14/15/3653cutaneous squamous cell carcinomaimmunotherapychemopreventionsolid organ transplant recipients |
| spellingShingle | Carrick Burns Shelby Kubicki Quoc-Bao Nguyen Nader Aboul-Fettouh Kelly M. Wilmas Olivia M. Chen Hung Quoc Doan Sirunya Silapunt Michael R. Migden Advances in Cutaneous Squamous Cell Carcinoma Management Cancers cutaneous squamous cell carcinoma immunotherapy chemoprevention solid organ transplant recipients |
| title | Advances in Cutaneous Squamous Cell Carcinoma Management |
| title_full | Advances in Cutaneous Squamous Cell Carcinoma Management |
| title_fullStr | Advances in Cutaneous Squamous Cell Carcinoma Management |
| title_full_unstemmed | Advances in Cutaneous Squamous Cell Carcinoma Management |
| title_short | Advances in Cutaneous Squamous Cell Carcinoma Management |
| title_sort | advances in cutaneous squamous cell carcinoma management |
| topic | cutaneous squamous cell carcinoma immunotherapy chemoprevention solid organ transplant recipients |
| url | https://www.mdpi.com/2072-6694/14/15/3653 |
| work_keys_str_mv | AT carrickburns advancesincutaneoussquamouscellcarcinomamanagement AT shelbykubicki advancesincutaneoussquamouscellcarcinomamanagement AT quocbaonguyen advancesincutaneoussquamouscellcarcinomamanagement AT naderaboulfettouh advancesincutaneoussquamouscellcarcinomamanagement AT kellymwilmas advancesincutaneoussquamouscellcarcinomamanagement AT oliviamchen advancesincutaneoussquamouscellcarcinomamanagement AT hungquocdoan advancesincutaneoussquamouscellcarcinomamanagement AT sirunyasilapunt advancesincutaneoussquamouscellcarcinomamanagement AT michaelrmigden advancesincutaneoussquamouscellcarcinomamanagement |